H. pylori eradication
Phase 3Small molecule
H. pylori eradication is one of 17 small molecule programs targeting Helicobacter Pylori Eradication. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Helicobacter Pylori Eradication
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Flagyl
DDePuy Orthopaedics
Approved
Takecab
PPhathom Pharmaceuticals, Inc.
Approved
Potassium Citrate
MMission Pharmacal
Approved
Levaquin
WWim Janssens
Approved
Aciphex
Akero TherapeuticsApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Minocin
TTriax
Approved
Furoxone
UUniversity of New Hampshire
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori Eradication2 trials
Gastric Neoplasm1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for H. pylori eradication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details